MODERN POSSIBILITIES OF OSTEOPOROSIS TREATMENT


A.V. Pashentseva, A.F. Verbovoy, O.V. Kosareva, L.A. Sharonova

Department of Endocrinology, SBEI HPE "Samara State Medical University" of RMPH, Samara
Osteoporosis - is a chronic disease of the skeleton, leading to bone fragility and fracture and requiring long-term treatment. The article deals with the modern principles of pathogenetic therapy of osteoporosis, summarizes data on the effectiveness of the main groups of drugs.

Literature


1. Kanis J.A. Оn behalf of the World Health Organization Scientific Group (2007). Assessment of osteoporosis at the primary health-care level. Technical Report. / World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK. 2007: Printed by University of Sheffield.

2. Johnell O., Kanis J.A. An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporosis International. 2004;15:897–902.

3. Лесняк О.М., Беневоленская Л.И. Остеопороз в Российской федерации: проблемы и перспективы. Научно-практическая ревматология. 2010;5:14–8.

4. Меньшикова Л.В., Храмцова Н.А., Ершова О.Б. и др. Ближайшие и отдаленные исходы переломов проксимального отдела бедра у лиц пожилого возраста и их медикосоциальные последствия (по данным многоцентрового исследования). Остеопороз и остеопатии. 2002;1:8–11.

5. Остеопороз / Под ред. О.М. Лесняк, Л.И. Беневоленской. 2-е изд., перераб. и доп. М., 2010. 272 с.

6. Devine A., Prince R.L., Dhalival S.S., et al. Results of a 5 Year Double Blinde, Placebo Controlled Trial of Calcium Supplementation (CAIFOS): Bone Density Outcomes. J. Bone Miner. Res. 2004;SA416.

7. Никитинская О.А., Торопцова Н.В. Социальная программа «Остеоскрининг Россия» в действии. Фарматека. 2012;6:90–3.

8. Boonen S., Lips P., Bouillon R., Bischoff-Ferrari H.A., Vanderschueren D., Haentjens P. Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J. Clin. Endocrinol. Metabol. 2007;92 (4):1415–23.

9. Лесняк О.М., Никитинская О.А., Торопцова Н.В. и др. Профилактика, диагностика и лечение дефицита витамина D и кальция у взрослого населения России и пациентов с остеопорозом (по материалам подготовленных клинических рекомендаций). Научно-практическая ревматология. 2015;4:403–8.

10. Pols H.A., Felsenberg D., Hanley D.A, Stepan J., Munoz-Torres M., Wilkin T.J., Qin-sheng G., Galich A.M., Vandormael K., Yates A.J., Stych B. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT Study. Osteoporos Int. 1999;9(5):461–68.

11.Black D.M., Thompson D.E., Bauer D.C.; FIT Research Group. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J. Clin. Endocrinol. Metab. 2000;85(11):4118–24.

12. BlackD.M.,SchwartzA.V.,EnsrudK.E.,CauleyJ.A., Levis S., Quandt S.A., Satterfield S., Wallace R.B., Bauer D.C., Palermo L., Wehren L.E., Lombardi A., Santora A.C., Cummings SREffects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927–38.

13. Rizzoli R., Greenspan S.L., Bone G. 3rd, Schnitzer T.J., Watts N.B., Adami S., Foldes A.J., Roux C., Levine M.A., Uebelhart B., Santora A.C. 2nd, Kaur A., Peverly C.A., Orloff J.J. Twoyear results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J. Bone Miner. Res. 2002;17:1988–96.

14. Wells G.A., Cranney A., Peterson J., Boucher M., Shea B., Robinson V., Coyle D., Tugwell P. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst. Rev. 2008;23(1):CD001155.

15.Chesnut C.H., Skag A., Christiansen C. 3rd, Skag A., Stakkestad J.A., Emkey R., Gilbride J., Schimmer R.C., Christiansen C. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res. 2004;19:1241–49.

16. Miller P.D., McClung M., Macovei I., Stakkestad J.A., Luckey M., Bonvoisin B., Reginster J.Y., Recker R.R., Hughes C., Lewiecki E.M., Felsenberg D., Delmas P.D., Kendler D.L., Bolognese M.A., Mairon N., Cooper C. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J. Bone Miner. Res. 2005;20:1315–22.

17. Delmas P.D., Adami S., Strugala C., Stakkestad J.A., Reginster J.Y., Felsenberg D., Christiansen C., Civitelli R., Drezner M.K., Recker R.R., Bolognese M., Hughes C., Masanauskaite D., Ward P., Sambrook P., Reid D.M. Intravenous ibandronate injections in postmenopausal osteoporosis: 1-year findings from the DIVA Study. Arthritis Rheum. 2006;54:1838–46.

18. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., Cosman F., Lakatos P., Leung P.C., Man Z., Mautalen C., Mesenbrink P., Hu H., Caminis J., Tong K., Rosario-Jansen T., Krasnow J., Hue T.F., Sellmeyer D., Eriksen E.F., Cummings S.R. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 2007;356(18):1809–22.

19. Black D., Reid I., Boonen S, Bucci-Rechtweg C., Cauley J.A., Cosman F., Cummings S.R., Hue T.F., Lippuner K., Lakatos P., Leung P.C., Man Z., Martinez R.L., Tan M., Ruzycky M.E., Su G., Eastell R. The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment in Osteoporosis: a Randomized Extension to the HORIZONPivotal Fracture Trial (PFT). J. Bone Miner. Res. 2012;27(2):243–54.

20. Reginster J.Y., Seeman E., De Vernejoul M.C., Adami S., Compston J., Phenekos C., Devogelaer J.P., Curiel M.D., Sawicki A., Goemaere S., Sorensen O.H., Felsenberg D., Meunier P.J. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis treatment of peripheral osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab. 2005;90:2816–22.

21. European Medicines Agency (2012) Questions and answers on the review of Protelos and Osseor (strontium ranelate). http://www.ema. europa.eu/docs/en_GB/document_library/Medicine_QA/2012/03/WC500124208.pdf.

22.Wells G., Tugwell P., Shea B., Guyatt G., Peterson J., Zytaruk N., Robinson V., Henry D., O’Connell D., Cranney A. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr. Rew. 2002;23:529–39.

23. Writing Group for the Women’s Health Initiative. Risks and Benefits of Estrogen plus Progestin in Healthy Postmenopausal Women. Principal results from the Women’s Health Initiative Randomized Controlled Trial. JAMA. 2002;288:321–33.

24. Ettinger B., Black D.M., Mitlak B.H. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA. 1999;282:637–45.

25. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich GA, Reginster J.Y., Hodsman A.B., Eriksen E.F., Ish-Shalom S., Genant H.K., Wang O., Mitlak B.H. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 2001;344:1434–41.

26. Рожинская Л.Я., Арапова С.Д., Дзеранова Л.К. и др. Исследование эффективности и безопасности терапии терипаратидом (Форстео) в течение 1 года при постменопаузальном остеопорозе. Остеопороз и остеопатии. 2006;2:6–12.

27. Chesnut C.H., Silverman S., Andriano K., Prince R., Gaich G.A., Reginster J.Y., Hodsman A.B., Eriksen E.F., Ish-Shalom S., Genant H.K., Wang O., Mitlak B.H. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Amer. J. Med. 2000;109:267–76.

28. European Medicines Agency (2012) Questions and answers on the review of calcitonin-containing medicine. EMEA, http://www.ema.europa. eu/docs/en_GB/document_library/Referrals_ document/Calcitonin_31/WC500130149.pdf.

29. McClung M.R., Lewiecki E.M., Cohen S.B., Bolognese M.A., Woodson G.C., Moffett A.H., Peacock M., Miller P.D., Lederman S.N., Chesnut C.H., Lain D., Kivitz A.J., Holloway D.L., Zhang C., Peterson M.C., Bekker P.J. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 2006;354(8):821–31.

30. Cummings S.R., San Martin J., McClung M.R., Siris E.S., Eastell R., Reid I.R., Delmas P., Zoog H.B., Austin M., Wang A., Kutilek S., Adami S., Zanchetta J., Libanati C., Siddhanti S., Christiansen C. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 2009; 361:756–65.

31. Brown J.P., Prince R.L., Deal Chad, Recker R.R., Kiel D.P., de Gregorio L.H., Hadji P., Hofbauer L.C., Alvaro-Gracia J.M., Wang H., Austin M., Wagman R.B., Newmark R., Libanati C., San Martin J., Bone H.G. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomised, blinded, Phase 3 trial. J. Bone Mineral. Res. 2009;24:153–61.

32. Ершова О.Б., Лесняк О.М., Белова К.Ю. и др. Предварительные результаты открытого наблюдательного исследования по оценке эффективности и безопасности применения препарата Пролиа у женщин с постменопаузальным остеопорозом. Тер. архив. 2014;86(10):60–4.


About the Autors


A.F. Verbovoy – Doctor of Medical Sciences, Prof, Head of the Department of Endocrinology SBEI HPE Samara State Medical University of RMPH, Samara; e-mail: andreyy.verbovoyy@rambler.ru


Similar Articles


Бионика Медиа